1.86
-0.11(-5.58%)
Currency In USD
Address
55 Park Lane
London, W1K 1NA
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 7495 2379
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
November 20, 2018
| Name | Title | Pay | Year Born |
| Dr. Ivor R. Elrifi Ph.D. | Chief Executive Officer & Executive Director | 131,000 | N/A |
| Mr. Gabriele Marco Antonio Cerrone M.B.A. | Founder & Executive Chairman | 1.85M | 1972 |
| Ms. Keeren Shah | Chief Operating Officer & Chief Financial Officer | 0 | 1976 |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer | 0 | N/A |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board | 0 | 1957 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.